Skip to content

Comparison of the effects of Oral Montelukast with Oral Zileuton in sudden attack of asthma.

Comparison of the effects of Oral Montelukast with Oral Zileuton in acute asthma - A prospective, randomized, double blinded study.

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/12/004260
Enrollment
120
Registered
2013-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute exacerbation of Bronchial Asthma

Interventions

Intervention1: Montelukast: Patients in the montelukast arm will be given oral montelukast 10 mg once daily, in addition to the standard treatment for asthma exacerbation from the day of admission til

Sponsors

Dr Shahul Hameed Aboobackar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 65. 2. Previously diagnosed case of bronchial asthma. 3. A primary diagnosis of acute exacerbation of asthma on presentation. 4. Peak expiratory flow rate (PEFR) less than or equal to 75% of personal best within the last 12 months or of predicted value. 5. No other acute pathology complicating the present condition like cardiac, metabolic or other respiratory causes.

Exclusion criteria

Exclusion criteria: 1. Smoking history more than 10 pack years. 2. Pregnant females. 3. Breast feeding females. 4. Patient on regular Leukotriene receptor antagonists or 5 lipoxygenase inhibitors within 2 weeks of presentation. 5. Intake of oral or parenteral steroids for > 5 days within one month of presentation. 6. Intake of theophylline within one week of presentation. 7. Need of intubation before presentation. 8. Patients on regular RifampIcin, Phenytoin or Phenobarbitone.

Design outcomes

Primary

MeasureTime frame
Percentage change in PEFR (Peak expiratory flow rate)from baseline.Timepoint: 6 hrs 12 hrs 24 hrs and 48 hrs following administration of study drug and at discharge.

Secondary

MeasureTime frame
Number of times rescue medications were required.Timepoint: Any time from the administration of study drug to the time of discharge.

Countries

India

Contacts

Public ContactDr Shahul Hameed Aboobackar

Kasturba Medical College Manipal

rahulmagazine@gmail.com00919901727204

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026